Voriconazole phototoxicity in children: A retrospective review

Sheu, Johanna; Hawryluk, Elena B.; Guo, Deliang; London, Wendy B.; Huang, Jennifer T.

doi:10.1016/j.jaad.2014.10.023

Cited by 53 publications

(30 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Photosensitivity is reported to occur in 1%‐2% of patients receiving voriconazole and may be more common in patients treated for prolonged periods . Others have reported much higher rates of photosensitivity (10%‐20%) . Photosensitivity reactions may include erythema, cheilitis, discoid lupus‐like lesions, blistering, solar elastosis, lentigines, desquamation, hyperpigmentation, and pseudoporphyria (Figure ).…”

Section: Methodsmentioning

confidence: 99%

Adverse effects of voriconazole: Over a decade of use

Levine

Chandrasekar

2016

Clinical Transplantation

114

View full text Add to dashboard Cite

Voriconazole use has increased since the drug's introduction in 2002, and new and unique adverse effects are emerging as patients undergo prolonged therapy. Most concerning is the increased risk of cutaneous malignancies, primarily squamous cell carcinoma (SCC); this risk is duration dependent and the associated malignancies tend to be more aggressive and multifocal. Voriconazole is also associated with phototoxicity (which may be a precursor to malignancy), periostitis, hallucinations and encephalopathy, peripheral neuropathy, alopecia, nail changes, hyponatremia, and other adverse effects. Some toxicities (neuropsychiatric and gastrointestinal including hepatic) are seen in clear association with supratherapeutic serum voriconazole levels; thus, careful monitoring of voriconazole levels is a critical component of safe drug use. Guidelines for screening for adverse effects after long-term voriconazole use may be beneficial and need to be established.

show abstract

Section: Methodsmentioning

confidence: 99%

Adverse effects of voriconazole: Over a decade of use

Levine

Chandrasekar

2016

Clinical Transplantation

114

View full text Add to dashboard Cite

show abstract

“…Some skin diseases can be drug‐induced; for example, Voriconazole, HCTZ, and Amiloride induce SCC . We speculate that combining these drugs with IL‐1α monoclonal antibody may have a valuable therapeutic advantage.…”

Section: Current and Potential Treatmentsmentioning

confidence: 99%

The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha

et al. 2016

View full text Add to dashboard Cite

Inflammation plays a major role in the induction and progression of several skin diseases. Overexpression of the major epidermal proinflammatory cytokines interleukin (IL) 1 alpha (IL-1α) and 1 beta (IL-1β) is positively correlated with symptom exacerbation and disease progression in psoriasis, atopic dermatitis, neutrophilic dermatoses, skin phototoxicity, and skin cancer. IL-1β and the interleukin-1 receptor I (IL-1RI) have been used as a therapeutic target for some autoinflammatory skin diseases; yet, their system-wide effects limit their clinical usage. Based on the local effects of extracellular IL-1α and its precursor, pro-IL-1α, we hypothesize that this isoform is a promising drug target for the treatment and prevention of many skin diseases. This review provides an overview on IL-1α and IL-β functions, and their contribution to inflammatory and malignant skin diseases. We also discuss the current treatment regimens, and ongoing clinical trials, demonstrating the potential of targeting IL-1α, and not IL-1β, as a more effective strategy to prevent or treat the onset and progression of various skin diseases.

show abstract

“…Most reports have been in children, with incidence reported to be as high as 20% [55], and 10.5% in patients aged over 12 years [56]. However, neither study was specific to patients who had received alloHSCT.…”

Section: Adverse Eventsmentioning

confidence: 99%

Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation

Marks

Liu

Slavin

2017

Expert Review of Anti-infective Therapy

View full text Add to dashboard Cite

Introduction: Invasive fungal infections (IFIs) following allogeneic hematopoietic stem cell transplantation (alloHSCT) are associated with a high mortality, and accordingly most alloHSCT recipients receive prophylaxis with antifungal agents. Despite some improvement in outcomes of IFIs over time, they continue to represent substantial clinical risk, mortality, and financial burden. Areas covered: We review the main pathogens responsible for IFIs in recipients of alloHSCT, current treatment recommendations, and discuss clinical and economic considerations associated with voriconazole prophylaxis of IFIs in these patients. Expert commentary: The clinical efficacy of voriconazole appears to be at least equivalent to other antifungal treatments, and generally well tolerated. Overall, benefit-risk balance is favorable, and findings from cost-effectiveness analyses support the use of voriconazole prophylaxis of IFIs in recipients of alloHSCT.ARTICLE HISTORY

show abstract

Voriconazole phototoxicity in children: A retrospective review

Cited by 53 publications

References 25 publications

Adverse effects of voriconazole: Over a decade of use

Adverse effects of voriconazole: Over a decade of use

The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha

Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation

Contact Info

Product

Resources

About